Market Place
Sourcing Support
Cerevance’s CVN293 Shows Positive Ph1 Results in Healthy Volunteers
11 Nov 2024 //
GLOBENEWSWIRE
Cerevance Publishes Ph 2 Results Of Solengepras For Parkinson
21 Oct 2024 //
GLOBENEWSWIRE
Sarah Sheikh Joins Cerevance’s Board of Directors
17 Oct 2024 //
GLOBENEWSWIRE
Cerevance Achieves Second Milestone In Merck Collaboration
08 Oct 2024 //
GLOBENEWSWIRE
Cerevance To Join Panel At Fierce Biotech Summit 2024
23 Sep 2024 //
GLOBENEWSWIRE
Cerevance Appoints Sagar Vaidya, M.D. Ph.D., as Chief Medical Officer
12 Aug 2024 //
GLOBENEWSWIRE
Cerevance Presents At FENS Forum 2024
18 Jun 2024 //
GLOBENEWSWIRE
Cerevance To Participate In Precision Neurotherapeutics BIO Panel
20 May 2024 //
GLOBENEWSWIRE
Cerevance Presents At Parkinson`s World Congress 2024
09 May 2024 //
GLOBENEWSWIRE
Cerevance Achieves First Milestone in Research Collaboration with Merck
02 May 2024 //
GLOBENEWSWIRE
Cerevance to Participate at Upcoming Investor Conferences
29 Apr 2024 //
GLOBENEWSWIRE
Cerevance Raises $47M Series B-1 Extension To Advance Clinical Pipeline
25 Apr 2024 //
GLOBENEWSWIRE
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
22 Apr 2024 //
GLOBENEWSWIRE
Cerevance Presents at Medicinal Chemistry Symposium in Eastern England
17 Apr 2024 //
GLOBENEWSWIRE
Cerevance to Participate at the 23rd Annual Needham Virtual Health Conference
02 Apr 2024 //
GLOBENEWSWIRE
Cerevance Announces Presentation at Alzheimer™s Research UK Conference
13 Mar 2024 //
GLOBENEWSWIRE
Cerevance Announces Presentation at AD/PD„¢ 2024 International Conference
27 Feb 2024 //
GLOBENEWSWIRE
Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
22 Feb 2024 //
GLOBENEWSWIRE
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Letters
15 Feb 2024 //
GLOBENEWSWIRE
Cerevance to Participate in Fireside Chat at RBC Markets Healthcare Conference
05 Dec 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
28 Nov 2023 //
GLOBENEWSWIRE
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424
13 Nov 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting
07 Nov 2023 //
GLOBENEWSWIRE
Cerevance to Participate at the Wells Fargo 2023 Private Biotech Symposium
25 Oct 2023 //
GLOBENEWSWIRE
Cerevance to Participate at the Leerink Biopharma Private Company Connect
18 Oct 2023 //
GLOBENEWSWIRE
Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum
10 Oct 2023 //
GLOBENEWSWIRE
Cerevance to Participate at the 2023 Life Sciences Private Company Showcase
04 Oct 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at Neuropsychopharmacology Congress
02 Oct 2023 //
GLOBENEWSWIRE
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293
19 Sep 2023 //
GLOBENEWSWIRE
Cerevance to Present During the 6th Annual LSX World Congress USA
06 Sep 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at the 22nd Society of Chemical Industry
31 Aug 2023 //
GLOBENEWSWIRE
Fierce Biotech Names Cerevance a €œFierce 15€ Biotech Company of 2023
28 Aug 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at the International Conference
10 Jul 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at the XVI European Meeting
28 Jun 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at the Gordon Research Conference
26 Jun 2023 //
GLOBENEWSWIRE
Cerevance Announces Oral Presentation of Ph 1 Data on CVN766 at (ASCP)
16 May 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at Neurodegeneration: New Biology
09 May 2023 //
GLOBENEWSWIRE
Cerevance to Present at the 2023 RBC Capital Markets Global Healthcare
08 May 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at BNA International Festival of Neuroscience
13 Apr 2023 //
GLOBENEWSWIRE
Cerevance to Present at the Needham Healthcare Conference
10 Apr 2023 //
GLOBENEWSWIRE
Cerevance to Participate in Chief Medical Officer Summit 360Ëš
27 Mar 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentations at Two Medicinal Chemistry Conferences
21 Mar 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentations at AD/PD 2023 International Conference
20 Mar 2023 //
GLOBENEWSWIRE
Cerevance Announces Presentation at the Alzheimer`s UK Conference 2023
07 Mar 2023 //
GLOBENEWSWIRE
Cerevance Expands Series B Financing with Additional $51 Million
13 Feb 2023 //
GLOBENEWSWIRE
Third time’s the charm: Cerevance’s Series B expands again
13 Feb 2023 //
ENDPTS
Cerevance to Participate at the SVB Global Biopharma Conference
24 Jan 2023 //
GLOBENEWSWIRE
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766
09 Jan 2023 //
GLOBENEWSWIRE
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Conference
07 Dec 2022 //
GLOBENEWSWIRE
CSHL Neurodegenerative Diseases Biology & Therapeutics Conference Publication
30 Nov 2022 //
GLOBENEWSWIRE
Cerevance Announces Presentation of Study Results at Neuroscience Conference
15 Nov 2022 //
GLOBENEWSWIRE
Cerevance to Present at the Society for Neuroscience (SFN) 2022
07 Nov 2022 //
GLOBENEWSWIRE
Cerevance establishes strategic research collaboration with Merck
10 Aug 2022 //
PHARMA TIMES
Merck is back in Alzheimer`s saddle with $1B+ Cerevance pact
10 Aug 2022 //
FIERCEBIOTECH
Cerevance to Present During the 5th Annual LSX World Congress USA
16 Jun 2022 //
GLOBENEWSWIRE
Cerevance to Participate in Panel Discussion During the 2022 BIO
08 Jun 2022 //
GLOBENEWSWIRE
Cerevance outlines Phase II/III trial planned for Q1 2023
23 May 2022 //
CLINICALTRIALSARENA
Cerevance: Leadership Transition in Novel Therapeutics for Brain Diseases
19 Apr 2022 //
GLOBENEWSWIRE
Positive results for Cerevance’s Parkinson’s drug
31 Mar 2022 //
PHARMATIMES
Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424
31 Mar 2022 //
GLOBENEWSWIRE
